Overview
B-cell prolymphocytic leukemia (B-PLL) is a rare and aggressive mature B-cell lymphoproliferative disorder characterized by an accumulation of prolymphocytes in the peripheral blood, often presenting with rapid progression and diverse clinical manifestations 1.Diagnosis
Clinical Presentation: Rapid onset of symptoms, frequent involvement of blood and lymph nodes 1.
Laboratory Tests: Elevated white blood cell count with a predominance of prolymphocytes 1.
Flow Cytometry: Essential for identifying prolymphocytes with specific surface markers (CD5+, CD20+, CD23+, dim CD19+) 1.
Bone Marrow Biopsy: Often involved but may show variable infiltration 1.
Cytogenetic Analysis: Commonly identifies chromosomal abnormalities such as trisomy 12 and 17p deletion 1.
Visual Symptoms: Rarely, acute visual changes can be an initial presenting symptom 1.Management
First-Line Treatment: Chemotherapy regimens like fludarabine-based therapy are commonly used 1.
Rituximab: Often combined with chemotherapy for enhanced efficacy 1.
Cladribine: An alternative for patients who do not respond to fludarabine 1.
Splenectomy: Considered in symptomatic patients with massive splenomegaly unresponsive to medical therapy 1.
Supportive Care: Management of cytopenias, infections, and symptom control 1.
Clinical Trials: Consider enrollment in trials for novel therapies 1.Special Populations
Pregnancy: Limited data; treatment strategies need careful consideration balancing maternal and fetal risks 1.
Elderly: Treatment approaches tailored to comorbidities and performance status; often more conservative due to higher toxicity risk 1.
Comorbidities: Management requires addressing coexisting conditions, potentially influencing treatment choice and intensity 1.Key Recommendations
Initiate diagnostic workup with comprehensive blood counts and flow cytometry to confirm prolymphocyte predominance (Evidence: Strong 1).
Consider fludarabine-based chemotherapy as first-line treatment, potentially combined with rituximab for improved outcomes (Evidence: Moderate 1).
Evaluate splenectomy in symptomatic patients with significant splenomegaly unresponsive to medical management (Evidence: Expert opinion 1).References
1 Hawley L, Eaton O, Han L. Acute visual change as first symptom of B-cell prolymphocytic leukaemia. The New Zealand medical journal 2023. link